bioRxivCancer Biology
Colorectal cancer progression is potently reduced by a glucose-free, high-protein diet: comparison to anti-EGFR therapy
K. Skibbe, A.-K. Brethack, A. Suenderhauf, M. Ragab, A. Raschdorf, M. Hicken, H. Schlichting, J. Preira, J. Brandt, D. Castven, B. Foeh, R. Pagel, J. U. Marquardt, C. Sina, S. Derer
Abstract
Background & AimsTo enable rapid proliferation, colorectal tumor cells up-regulate epidermal growth factor receptor (EGFR) signaling and perform high level of aerobic glycolysis, resulting in substantial lactate release into the tumor microenvironment and impaired anti-tumor immune responses. We hypothesized that an optimized nutritional intervention designed to reduce aerobic glycolysis of tumor cells may boost EGFR-directed antibody (Ab)-based therapy of pre-existing colitis-driven colorectal carcinoma (CRC). MethodsCRC development was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS) administration to C57BL/6 mice. AOM/DSS treated mice were fed a glucose-free, high-protein diet (GFHPD) or an isoenergetic control diet (CD) in the presence or absence of i.p. injection of PBS, an irrelevant control mIgG2a or an anti-EGFR mIgG2a. Ex vivo, health status, tumor load, metabolism, colonic epithelial cell differentiation and immune cell infiltration were studied. Functional validation was performed in murine and human CRC cell lines MC-38 or HT29-MTX. ResultsAOM/DSS treated mice on GFHPD displayed reduced systemic glycolysis, resulting in improved tumoral energy homeostasis and diminished tumor load. Comparable but not additive to an anti-EGFR-Ab therapy, GFHPD was accompanied by enhanced tumoral differentiation and decreased colonic PD-L1 and splenic PD-1 immune checkpoint expression, presumably promoting intestinal barrier function and improved anti-tumor immune responses. In vitro, glucose-free, high-amino acid culture conditions reduced proliferation but improved differentiation of CRC cells in combination with down-regulation of PD-L1 expression. ConclusionWe here found GFHPD to metabolically reprogram colorectal tumors towards balanced OXPHOS, thereby improving anti-tumor T-cell responses and reducing CRC progression with a similar efficacy as EGFR-directed antibody therapy. SynopsisConsumption of glucose-free, high protein diet (GFHPD), comparable to EGFR-directed antibody-based therapy, efficaciously dampens colorectal tumor burden but does not have additive effects in combination with anti-EGFR therapy. GFHPD boosts amino acid metabolism, resulting in improved tumor differentiation and anti-tumor immune responses. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=81 SRC="FIGDIR/small/448354v1_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@e0c8fforg.highwire.dtl.DTLVardef@1abee36org.highwire.dtl.DTLVardef@a41e22org.highwire.dtl.DTLVardef@b678ab_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Microenvironmental Ammonia Enhances T cell Exhaustion in Colorectal Cancer
Y. M. Shah, H. Bell, … M. Green·bioRxiv·May 25, 2022
- Requirement of hypoxia-inducible factor 1 alpha for interleukin 1 beta induced glycolysis in colorectal cancer cells
Ji Yeon Kim, Bohye Park, … Dallas R. Donohoe·bioRxiv·Aug 19, 2026
- IL-1R signaling drives enteric glia-macrophage interactions in colorectal cancer
L. van Baarle, V. De Simone, … G. Matteoli·bioRxiv·Jun 1, 2023
- An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer
J. Jacob, L. E. Francisco, … K. S. Carmon·bioRxiv·Aug 11, 2022
- Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer
J. Jacob, Y. Anami, … K. S. Carmon·bioRxiv·Feb 20, 2024
- Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia
M. Ferrer, N. Mourikis, … T. Janowitz·bioRxiv·Feb 17, 2023